Business Update & Financial Outlook

Strong underlying Q2 worldwide sales growth Merck WORLDWIDE SALES1,2 $15.0B +3% growth +11% ex-LAGEVRIO3 +14% ex-exchange, ex-LAGEVRIO3 Human Health $13.5B +6% growth +14% ex-LAGEVRIO3 +17% ex-exchange, ex-LAGEVRIO3 Animal Health $1.5B -1% growth +2% ex-exchange 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $203 million in 2Q23 and $1.2 billion in 2Q22. MERCK 10

View entire presentation